Shanghai Bio-Forum Focuses On Patent Protection And Drug Pricing
This article was originally published in PharmAsia News
Patent protection and drug pricing were hot issues at the recent Conference of Chinese Biopharmaceutical Association and Shanghai Bio-Forum. Delegates agreed that patent protection is a prerequisite of collaboration and represents a key factor that is irreplaceable in the trend of global cooperation. China's laws and regulations on patent and intellectual property protection are well-received but overseas investors and partners expressed concern on the effectiveness of their long-term implementation. Opportunities for collaboration abound in the biopharmaceutical process and China offers the common language of an internationally recognized GMP system. (Click here for more - Chinese Language)
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.